It was a breakthrough for Marc Beer after he closed a $32 million Series B round. This amount adds to the $10 million that he has in venture debt and will be used to purchase new products for pelvic floor disorder. The world-famous entrepreneur has been raising money to support female health startups. His company, Renovia Inc. is based in Boston and has been on a mission to find enough funds to support its operations, specifically, therapeutic and diagnostics products that will be used for the management of diseases such as urinary incontinence.
About Urinary Incontinence
It is estimated that Urinary Incontinence affects about 250 million women from across the world. With Renovia having had its first product, Leva approved, there is no doubt that the company now has time and money to come up with even better solutions for their customers. The company revealed that four therapeutic and diagnostic products would be developed and tested. It was also announced that a new generation version of Leva and this is good news for the women who look forward to the company to come up with more innovative solutions to the problems that they face every day. Learn more: https://www.slideshare.net/MarcBeer
Associating with like-minded partners
While announcing the deal, Marc Beer said that he was thrilled to be associated with a group of the best healthcare investors. He particularly pointed out that since they share the same vision, there is no doubt that they will get along well, and they will formulate products that solve most of the problems that women go through. Also, he said that their goal was not only to diagnose but also to treat and better the lives of their customers who suffer without a reliable solution. However, he did not respond to questions about the pipeline of products that they want to develop or the investment in general.
More technologies for improved solutions
In addition to that, Mr. Marc Beer said that they plan to combine their innovative proprietary sensor technologies. This move, he said, will help them to form factors that relate to the digital health platform. The result is that customers will have high-quality data that enables them to find new treatments. They will also drive greater knowledge and know a lot of information about pelvic floor disorders. It is expected that the funding will, in the long run, reduce the costs of treating this disorder.
Marc Beer is the CEO of Renovia Inc., a company that develops diagnostic devices for the treatment of pelvic floor disorder. He has been active in the industry for more than 25 years developing and commercializing pharmaceutical inventions. He also has made significant contributions to biotechnology have partnered with various companies to come up with multiple solutions.